# US 2022/0017948 A1 · Detection of specific hla alleles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017948 A1
- Document ID: US20220017948A1
- Status: Published application
- Kind: A1
- Application number: 17/353,234
- Filed: 2021-06-21
- Published: 2022-01-20
- Earliest claimed: 2020-06-23
- Applicants: Genomind, Inc.
- Inventors: Kathleen DAVIS; David ROBBINS
- Web page: https://patentgrep.com/patent/US20220017948A1

## CPC

- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12Q 1/6858: Allele-specific amplification
- C12Q 1/686: Polymerase chain reaction [PCR]
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 33/582: {with fluorescent label}
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A screening method is provided for a specific HLA allele in an individual, including but not limited to an HLA-A*31:01 allele. Also included are methods for treating an individual in need of a medication, which can induce ADRs associated with a specific HLA allele, and a kit including detection reagents used in the screening method.

## Claims

### Claim 1

A method of determining whether an individual carries an HLA-A*31:01 allele, comprising:
(A) performing a first polymerase chain reaction (PCR) assay designed to amplify a first genomic region from a biological sample obtained from the individual, the first genomic region encompassing the loci corresponding to SNPs rs1059449, rs41541222, rs1059457, rs79361534, and rs1059471, using a first set of PCR primers that flank the first genomic region, wherein: the first set of PCR primers comprises at least one of (i) a first primer that overlaps the locus corresponding to rs1059449 and is specific for the rs1059449 G>A SNP or (ii) a second primer that overlaps the locus corresponding to rs1059471 and is specific for the rs1059471 C>T SNP, wherein:
when the first set of PCR primers includes the first primer:
the locus corresponding to rs41541222 is either (i) overlapped by the first primer, wherein the first primer is specific for the rs41541222 G>T SNP or (ii) overlapped by a respective detection reagent in a set of one or more HLA-A*31:01 detection reagents, wherein the respective detection reagent overlaps with the locus corresponding to rs41541222 and is specific for the rs41541222 G>T SNP, and
the locus corresponding to rs1059471 is either (i) overlapped by the second allele-specific primer, which is included in the first set of primers or (ii) overlapped by a respective detection reagent in the set of one or more HLA-A*31:01 detection reagents, wherein the respective detection reagent overlaps with rs1059471 and is specific for the rs1059471 C>T SNP; and
when the first set of PCR primers includes the second primer:
the locus corresponding to rs1059449 is either (i) overlapped by the first primer, which is included in the first set of primers or (ii) overlapped by a respective detection reagent in the set of one or more HLA-A*31:01 detection reagents, wherein the respective detection reagent overlaps with rs1059449 and is specific for the rs1059449 G>A SNP, and
the locus corresponding to rs41541222 is either (i) overlapped by the first primer, wherein the first primer is specific for the rs41541222 G>T SNP or (ii) overlapped by a respective detection reagent in the set of one or more HLA-A*31:01 detection reagents, wherein the respective detection reagent overlaps with rs41541222 and is specific for the rs41541222 G>T SNP; and
(B) contacting the first PCR assay with the set of one or more HLA-A*31:01 detection reagents, wherein each respective detection reagent in the set of one or more HLA-A*31:01 detection reagents comprises a moiety that is detectable when the first genomic region is amplified and the respective detection reagent is capable of specifically binding to the first genomic region; and
(C) attempting to detect the set of one or more HLA-A*31:01 detection reagents, wherein:
a first detection reagent in the set of one or more HLA-A*31:01 detection reagents is specific for the presence of the reference G allele at the locus corresponding to the rs1059457 SNP,
a second detection reagent in the set of one or more HLA-A*31:01 detection reagents is specific for the presence of the reference G allele at the locus corresponding to the rs79361534 SNP,
when the entire set of one or more HLA-A*31:01 detection reagents is detected, the individual is deemed to be a carrier of the HLA-A*31:01 allele, and
when less than the entire set of one or more HLA-A*31:01 detection reagents is detected, the individual is deemed not to be a carrier of the HLA-A*31:01 allele, thereby determining whether the individual carries the HLA-A*31:01 allele.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first genomic region does not encompass the locus corresponding to the rs41562315 SNP.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first primer overlaps with the locus corresponding to rs41541222 and is specific for the rs41541222 G>T SNP.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first primer has a nucleotide sequence comprising at least 10 consecutive nucleotides of SEQ ID NO:1.

### Claim 5 (depends on 4)

The method of claim 4, wherein said first primer comprises a nucleic acid sequence of SEQ ID NO:38.

### Claim 6 (depends on 1)

The method of claim 1, wherein the second primer has a nucleotide sequence comprising at least 10 consecutive nucleotides of SEQ ID NO:11.

### Claim 7 (depends on 6)

The method of claim 6, wherein the second primer comprises a nucleic acid sequence of SEQ ID NO:39.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first set of PCR primers consists of the first primer and the second primer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the set of one or more HLA-A*31:01 detection reagents consists of a single HLA-A*31:01 detection reagent that is specific for (i) the presence of the reference G allele at the locus corresponding to the rs1059457 SNP and (ii) the presence of the reference G allele at the locus corresponding to the rs79361534 SNP.

### Claim 10 (depends on 9)

The method of claim 9, wherein the single HLA-A*31:01 detection reagent comprises a nucleic acid sequence of SEQ ID NO:40 or SEQ ID NO:41.

### Claim 11 (depends on 1)

The method of claim 1, wherein each respective detection reagent in the set of one or more HLA-A*31:01 detection reagents is conjugated to one or more detection label.

### Claim 12 (depends on 11)

The method of claim 11, wherein the one or more detection label comprises a fluorescent dye.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more detection label comprises a matching pair of electronic energy transfer fluorophores comprising a donor fluorophore and a quencher fluorophore for the donor fluorophore.

### Claim 14 (depends on 1)

The method of claim 1, wherein contacting in (B) comprises adding the set of one or more HLA-A*31:01 detection reagents to the PCR assay prior to performing (A).

### Claim 15 (depends on 1)

The method of claim 1, wherein contacting in (B) comprises contacting the set of one or more HLA-A*31:01 detection reagents with a product of the PCR assay performed in (A).

### Claim 16 (depends on 1)

The method of claim 1, wherein the first PCR assay is a quantitative real-time PCR assay.

### Claim 17 (depends on 1)

The method of claim 1, wherein:
the first PCR assay is a multiplex PCR assay using a second set of PCR primers designed to amplify a control genomic locus from the biological sample obtained from the individual; and
the first PCR assay is contacted with a control detection reagent that binds to the control genomic locus.

### Claim 18 (depends on 17)

The method of claim 17, wherein:
the set of one or more HLA-A*31:01 detection reagents consists of a single HLA-A*31:01 detection reagent that is specific for (i) the presence of the reference G allele at the locus corresponding to the rs1059457 SNP and (ii) the presence of the reference G allele at the locus corresponding to the rs79361534 SNP;
the single HLA-A*31:01 detection reagent is conjugated to a first matching pair of electronic energy transfer fluorophores comprising a first donor fluorophore and a first quencher fluorophore for the first donor fluorophore; and
the control detection reagent is conjugated to a second matching pair of electronic energy transfer fluorophores comprising a second donor fluorophore and a second quencher fluorophore for the second donor fluorophore.

### Claim 19 (depends on 18)

The method of claim 18, wherein the first and the second matching pairs of electronic energy transfer fluorophores are selected from the group consisting of FAM-TAMRA, VIC-TAMRA, TET-TAMRA and JOE-TAMRA, and wherein the first and the second matching pairs of electronic energy transfer fluorophores are different.

### Claim 20 (depends on 1)

The method of claim 1, further comprising determining whether the individual is a carrier of the rs1061235 A>T SNP, wherein when it is determined that the individual does not carry the rs1061235 A>T SNP, the individual is deemed not to be a carrier of the HLA-A*31:01 allele.

### Claim at position 21

21-68. (canceled)
